Area of research
Cancer Research · Pulmonary and Respiratory Medicine
Research interest
Research interests include Medicine, Cancer research, Breast cancer, Oncology, Fulvestrant, and Loss of heterozygosity.
Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial
Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer
Pan-Cancer Analysis of <i>BRCA1</i> and <i>BRCA2</i> Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity
Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma
Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study
Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors
Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).
The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA
Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer
Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus
PD60-01 CASTRATE RESISTANT TMPRSS2: ERG FUSION POSITIVE AND TMPRSS2: ERG WILD TYPE REFRACTORY ACINAR AND NEUROENDOCRINE PROSTATE CANCER DIFFER IN GENOMIC SIGNATURES AND OPPORTUNITIES FOR TARGETED AND IMMUNOTHERAPIES
Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling
Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer